Arman Qamar et al. JACC 2018;71:

Slides:

Advertisements

Similar presentations

TREATMENT Coagulopathy of Liver Failure. Fresh Frozen Plasma – Most effective way to correct hemostasis in patients with liver failure – Infusion (5-10mL/kg)

Advertisements

Teaching Liver cirrhosis with varices. Discussion  Approximately half of patients with cirrhosis have esophageal varices  One-third of all patients.

Bleeding time,clotting time, PT, and PTT

Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.

Hemostasis and Blood Coagulation

Anticoagulations and Coagulants

Investigation of Haemostasis MS. c. program Lab-9.

Anticoagulants and reversal

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.

Coagulation tests CBC- complete blood count

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.

AUB:Iatrogent Coagulopathy

APTT, activated partial thromboplastin time; CAD, coronary artery disease; DIC, disseminated intravascular coagulation; GI, gastrointestinal; INR, international.

Overuse of INR and PT Testing in Medical Inpatients

UR Medicine at Ridgeland Road Clinical Trials Central Laboratory

Alan Rozanski et al. JACC 2005;45:

Stephen W. Waldo et al. JACC 2008;51:

Bruised Black and Blue: Acquired Hypoprothrombinemia

Coagulation Cascade of the Newborn

Michala E.F. Pedersen et al. JACEP 2017;3:

Suggested approach to patients with dabigatran-associated bleeding

Bruised Black and Blue: Acquired Hypoprothrombinemia

Clyde W. Yancy et al. JACC 2017;70:

Irbedrin Group Training

Robert W. Yeh et al. JACC 2017;70:

Truman J. Milling, MD, Scott Kaatz, DO, MSc

“Reversing Direct Oral Anticoagulants”

Current Concepts in Anticoagulant Therapy

Daniel Frenkel et al. JACEP 2016;2:

Patrizio Lancellotti et al. JIMG 2016;9:

New oral anticoagulants—what the cardiothoracic surgeon needs to know

Menno V. Huisman, MD, PhD, John Fanikos, RPh, MBA

Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus C. Thorborg,

Dean J. Kereiakes et al. JACC 2017;70:

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Johannes Steiner et al. JACC 2017;70:

James E. Novak, Khalid Alamiri, Jerry Yee

Anticoagulant Reversal

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

Michala E.F. Pedersen et al. JACEP 2016;j.jacep

Mohit K. Turagam et al. JACEP 2017;3:

Khurram Nasir et al. JACC 2015;66:

Nicolaj C. Hansson et al. JACC 2016;68:

A. Kisilevsky, A.W. Gelb, M. Bustillo, A.M. Flexman

Kenshi Hayashi et al. JACEP 2016;2:

Björn Redfors et al. JACEP 2017;j.jacep

Shahrokh Javaheri et al. JACC 2017;69:

P. Michael Grossman et al. JCIN 2009;2:

Maria R. Costanzo et al. JCHF 2016;4:

Pamela E. Scott et al. JACC 2018;71:

Coagulopathy and blood component transfusion in trauma

Ayman A. Hussein et al. JACEP 2017;3:1-9

Björn Redfors et al. JACEP 2017;j.jacep

PCC dose per manufacturer’s instructions.

Shunt dysfunction: Is it suitable as the primary end point in transjugular intrahepatic portosystemic shunt trials? Jingzhi Cai, Wengang Guo, Chuangye.

Vegetative infection of transjugular intrahepatic portosystemic shunts

Leo F. Buckley et al. JCHF 2016;4:1-8

Giuseppe Gargiulo et al. JACC 2018;71:

Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation Mihoko Kawabata,

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Glenn N. Levine et al. JACC 2011;58:e44-e122

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Writing Committee Members et al. JACC 2018;j.jacc

Gianluigi Savarese et al. JCHF 2016;4:

Drug Summary Info Document Request / monitor Goal of therapy Action

Use Fixed low dose Prothrombin Complex Concentrate (Octaplex)

Presentation transcript:

Arman Qamar et al. JACC 2018;71:2162-2175 Management of Severe or Life-Threatening Bleeding in Patients With Liver Disease Who Are Taking OACs ACC = American College of Cardiology; aPTT = activated partial thromboplastin time; CBC = complete blood count; EGD = esophagogastroduodenoscopy; FXa = factor Xa; INR = international normalized ratio; IV = intravenous; LFTs = liver function tests; OAC = oral anticoagulant agent; PT = prothrombin time; TIPS = transjugular intrahepatic portosystemic shunt; 4F-PCC = 4 factor-prothrombin complex concentrate; 2° = secondary. Arman Qamar et al. JACC 2018;71:2162-2175 2018 American College of Cardiology Foundation